Georgia is currently home to 1927 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Recruiting
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Hepatocellular Carcinoma
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville, Georgia
Conditions: Type 2 Diabetes
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: Atlanta Diabetes Associates, Atlanta, Georgia
Conditions: Type 1 Diabetes
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Recruiting
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Local Institution - 0392, Fort Eisenhower, Georgia
Conditions: Carcinoma, Non-Small-Cell Lung
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Recruiting
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Georgia Clincal Research, Lawrenceville, Georgia
Conditions: Post Bariatric Hypoglycemia
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Chronic Kidney Disease and Hypertension
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Recruiting
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Augusta University Medical Center, Augusta, Georgia
Conditions: Acute Myeloid Leukemia
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Dermatology Affiliates Research Institute, LLC, Atlanta, Georgia
Conditions: Moderate to Severe Genital Psoriasis
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Recruiting
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Recruiting
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Augusta University Medical Center, Augusta, Georgia
Conditions: Multiple Myeloma
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criter... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/01/2025
Locations: Velocity Clinical Research - Savannah Neurology- Site Number : 8400061, Savannah, Georgia
Conditions: Multiple Sclerosis
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia
Conditions: Low Grade Serous Ovarian Cancer